Anti-6X His tag monoclonal antibody, clone 6F23

Directed enzyme prodrug therapy (DEPT) is a cancer chemotherapy strategy in which bacterial enzymes are delivered to a cancer site before prodrug administration, resulting in prodrug activation at the cancer site and more localized treatment. A major limitation to DEPT is the poor effectiveness of the most studied enzyme for the CB1954 prodrug, NfnB fromEscherichia coli, at concentrations suitable for human use. Much research into finding alternative enzymes to NfnB has resulted in the identification of the Xenobiotic reductases, XenA and XenB, which have been shown in the literature to reduce environmentally polluting nitro-compounds. In this study, they were assessed for their potential use in cancer prodrug therapy strategies. Both proteins were cloned into the pET28a+ expression vector to give the genetically modified proteins XenA-his and XenB-his, of which only XenB-his was active when tested with CB1954. XenB-his was further modified to include a cysteine-tag to facilitate direct immobilization on to a gold surface for future magnetic nanoparticle DEPT (MNDEPT) treatments and was named XenB-cys. When tested using high-performance liquid chromatography (HPLC), XenB-his and XenB-cys both demonstrated a preference for reducing CB1954 at the 4-nitro position. Furthermore, XenB-his and XenB-cys successfully induced cell death in SK-OV-3 cells when combined with CB1954. This led to XenB-cys being identified as a promising candidate for use in future MNDEPT treatments.

Envelope proteins of white spot syndrome virus (WSSV) play an important role in viral entry as well as in triggering host defences. To date, some main envelope proteins such as VP28, VP24 and VP19 have been expressed heterologously and proved effective in WSSV prevention. However, VP62, an envelope protein with hub function as well as better antigenicity, has not been focused on. In an attempt to prepare this protein for rapid purification and further functional analysis, N-terminus-truncated VP62 was expressed in Escherichia coli using two common fusion tags, including hexahistidine (his6) and solubility-enhancing tag thioredoxin (Trx). The results showed that the truncated VP62 fused with C-terminal His-tag could not be expressed in either E. coli BL21(Plyss) or Arctic Express, but it could be expressed in the form of inclusion bodies in Arctic Express with N-terminal tag. After refolding and His-tag affinity purification, the protein with purity over 90% was obtained. This study laid the foundation for evaluation of its vaccine potential as well as further application in WSSV prevention.